MA03.03 CEA and CYFRA 21-1 as Prognostic Biomarkers of Benefit from Nivolumab and as a Tool in Treatment Monitoring in Advanced NSCLC

Autor:	S. Buti, Marcello Tiseo, Francesco Facchinetti, Francesca Abbati, Barbara Melotti, Francesco Gelsomino, Filippo Gustavo Dall'Olio, Maria Massucci, Andrea Ardizzoni, Michele Veneziani
Rok vydání:	2019
Předmět:	Pulmonary and Respiratory Medicine Oncology medicine.medical_specialty business.industry Internal medicine medicine Nivolumab business CYFRA 21-1 Treatment monitoring
Zdroj:	Journal of Thoracic Oncology. 14:S257
ISSN:	1556-0864
DOI:	10.1016/j.jtho.2019.08.513
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::d4d4da0bdab55fdb22cfaca5858fadb5 https://doi.org/10.1016/j.jtho.2019.08.513 Zobrazit plný text záznamu